Dysregulation of the annexin family protein family is associated with prostate cancer progression

被引:152
作者
Xin, W
Rhodes, DR
Ingold, C
Chinnaiyan, AM
Rubin, MA
机构
[1] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA
[2] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI USA
[3] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI USA
关键词
D O I
10.1016/S0002-9440(10)63816-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Hormone refractory prostate cancer (PCa) is invariably lethal despite aggressive clinical treatment strategies. Detection strategies are needed to identify aggressive PCa before it becomes widely disseminated. Recently, two studies identified annexin 1 and 7 as potential biomarkers; in the development of PCa progression. The annexins are a group of calcium-binding structural proteins that may play a role in the regulation of membrane trafficking, cellular adhesion, and cell signaling. Therefore the goal of this study is to simultaneously characterize the multiple members of the annexin family of genes in advanced PCa. Prostate samples from men with advanced hormone refractory PCa were compared to samples of hormone-naive PCa and noncancerous prostate tissue. Samples from 15 patients with advanced hormone refractory PCa were used. To examine the annexin family, gene expression profiles from 21 noncancerous prostate tissues, 16 clinically localized PCas, and 20 hormone refractory PCa samples were used. By cDNA microarray analysis, annexins 1, 2, 4, 7, and 11 were significantly decreased in hormone refractory PCa when compared to localized hormone-naive PCa with 2.2-, 1.5-, 1.3-, 1.4-, and 1.8-fold decreases, respectively (all P values <0.05). Interstudy validation of annexin family transcript expression was performed by meta-analysis of three other published prostate profiling studies. High-density tissue microarrays were used to validate a subset of annexins at the protein level by immunohistochemistry. Tissue microarray analysis revealed a significant decrease in protein expression for annexins 1, 2 7 4, 7, and 11 in hormone refractory PCa as compared to localized PCa with 1.68-, 2.46-, 2.52-, and 3.01-fold decreases, respectively (Kruskal Wallis test, all P values P < 0.05). However, no significant differences were detected between the clinically localized PCa and noncancerous prostate tissues. These findings suggest that down-regulation of several members of the annexin family may contribute to PCa tumorigenesis. Annexins 1, 2, 4, 7, and 11 may play a role in tumor progression through distinct mechanisms or, alternatively, they may have redundant tumor suppressor activities. This study also suggests that a meta-analysis of existing gene expression data is useful in confirming findings from individual studies. Finally, down-regulation of several annexin family members may play a role in the development of the lethal PCa phenotype.
引用
收藏
页码:255 / 261
页数:7
相关论文
共 36 条
[1]   Molecular genetics of prostate cancer [J].
Abate-Shen, C ;
Shen, MM .
GENES & DEVELOPMENT, 2000, 14 (19) :2410-2434
[2]  
Bostwick D G, 1999, Semin Urol Oncol, V17, P222
[3]   COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE-SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE-CANCER - RESULTS OF A MULTICENTER CLINICAL-TRIAL OF 6,630 MEN [J].
CATALONA, WJ ;
RICHIE, JP ;
AHMANN, FR ;
HUDSON, MA ;
SCARDINO, PT ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 151 (05) :1283-1290
[4]  
CHAN HC, 1994, J BIOL CHEM, V269, P32464
[5]  
CHANG KS, 1992, BLOOD, V79, P1802
[6]   ELEVATED EXPRESSION OF ANNEXIN-II (LIPOCORTIN-II, P36) IN A MULTIDRUG RESISTANT SMALL-CELL LUNG-CANCER CELL-LINE [J].
COLE, SPC ;
PINKOSKI, MJ ;
BHARDWAJ, G ;
DEELEY, RG .
BRITISH JOURNAL OF CANCER, 1992, 65 (04) :498-502
[7]   Delineation of prognostic biomarkers in prostate cancer [J].
Dhanasekaran, SM ;
Barrette, TR ;
Ghosh, D ;
Shah, R ;
Varambally, S ;
Kurachi, K ;
Pienta, KJ ;
Rubin, MA ;
Chinnaiyan, AM .
NATURE, 2001, 412 (6849) :822-826
[8]   Cancer surveillance series: Interpreting trends in prostate cancer - Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality [J].
Etzioni, R ;
Legler, JM ;
Feuer, EJ ;
Merrill, RM ;
Cronin, KA ;
Hankey, BF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (12) :1033-1039
[9]  
GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125
[10]  
Hedges LV, 1985, STAT METHODS METAANA, p[xxii, 369]